BDSX - Biodesix announces research pact with top U.S. cancer center
Biodesix (NASDAQ:BDSX) aims to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Bio-Rad, Inc. In addition, the master sponsored research pact between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer. At first, the teams will collaborate to develop a highly sensitive molecular MRD test on the new ddPCR™ platform, the Bio-Rad QX600™ ddPCR™ System.
For further details see:
Biodesix announces research pact with top U.S. cancer center